Skip to main content
Log in

The Diagnosis and Treatment of Raynaud’s Phenomenon

A Practical Approach

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Raynaud’s phenomenon is a common disorder with vasospasm of the digital arteries causing pallor with cyanosis and/or rubor. It can be primary (idiopathic), where it is not associated with other diseases, or secondary to several diseases or conditions, including connective tissue diseases, such as scleroderma and systemic lupus erythematosus. Raynaud’s is often mild enough to not require treatment; however, with secondary Raynaud’s there is not only vasospasm but also fixed blood vessel defects so the ischaemia can be more severe. Complications can include digital ulcers and could, rarely, lead to amputation. Treatment is often non-pharmacological including avoiding cold and smoking cessation. Calcium channel antagonists, such as nifedipine, are often considered when treatment is needed; however, adverse effects of these drugs can include hypotension, vasodilatation, peripheral oedema and headaches. Other treatments have been studied in randomised, controlled trials including classes of drugs, such as angiotensin II inhibitors, selective serotonin reuptake inhibitors, phosphodiesterase-5 inhibitors (e.g. sildenafil), nitrates (topical or oral; the latter can be limited by adverse effects, such as flushing, headache and hypotension), and for more serious Raynaud’s or its complications prostacyclin agonists may be used. There are two large studies that demonstrate that endothelin receptor blockade with bosentan can reduce the number of new digital ulcers in scleroderma patients. However, it does not affect the healing period

Thus, Raynaud’s is common and often requires non-pharmacological treatment. When secondary Raynaud’s is suspected, such as Raynaud’s with an older age at onset or other features of connective tissue disease, then an appropriate history, physical examination and laboratory tests may be indicated to reach an appropriate diagnosis. There have been advances in pharmacological treatment, but some of the treatments are limited by adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Pope J. Raynaud’s phenomenon (primary). Clin Evidence 2003 Jun; 9: 1339–48

    Google Scholar 

  2. Herrick A. Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford) 2005 May; 44(5): 587–96

    Article  CAS  Google Scholar 

  3. White CR, Haidekker MA, Stevens HY, et al. Extracellular signal-regulated kinase activation and endothelin-1 production in human endothelial cells exposed to vibration. J Physiol 2004 Mar l; 555 (Pt 2): 565–72

    Article  PubMed  CAS  Google Scholar 

  4. Pistorius MA, Planchon B, Schott JJ, et al. Heredity and genetic aspects of Raynaud’s disease. J Mal Vasc 2006 Feb; 31(1): 10–5

    Article  PubMed  CAS  Google Scholar 

  5. Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol 2005 Nov; 17(6): 752–60

    PubMed  CAS  Google Scholar 

  6. Herrick A. Treatment of Raynaud’s phenomenon: new insights and developments. Curr Rheumatol Rep 2003 Apr; 5(2): 168–74

    Article  PubMed  Google Scholar 

  7. Ohtsuka T, Tamura T, Yamakage A, et al. The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. Br J Dermatol 1998 Oct; 139(4): 622–9

    Article  PubMed  CAS  Google Scholar 

  8. Bergman R, Sharony L, Schapira D, et al. The handheld dermatoscope as a nail-fold capillaroscopic instrument. Arch Dermatol 2003 Aug; 139(8): 1027–30

    Article  PubMed  Google Scholar 

  9. Pope JE, Black C, Matucci-Cerinic M, et al. Functional correlates of reduction of digital ulcers by bosentan therapy in patients with systemic sclerosis (SSc). Arthritis Rheum 2006; 54 Suppl. 9: S740

    Google Scholar 

  10. Eliasson K, Danielson M, Hylander B, et al. Raynaud’s phenomenon caused by beta-receptor blocking drugs: improvement after treatment with a combined alpha- and beta-blocker. Acta Med Scand 1984; 215(4): 333–9

    Article  PubMed  CAS  Google Scholar 

  11. Brotzu G, Falchi S, Mannu B, et al. The importance of presynaptic beta receptors in Raynaud’s phenomenon. J Vasc Surg 1989 Jun; 9(6): 767–71

    PubMed  CAS  Google Scholar 

  12. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford) 2005 Feb; 44: 145–50

    Article  CAS  Google Scholar 

  13. Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999 Dec; 42(12): 2646–55

    Article  PubMed  CAS  Google Scholar 

  14. Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001 Sep; 40(9): 1038–43

    Article  CAS  Google Scholar 

  15. Rustin MH, Almond NE, Beacham JA, et al. The effect of captopril on cutaneous blood flow in patients with primary Raynaud’s phenomenon. Br J Dermatol 1987 Dec; 117(6): 751–8

    Article  PubMed  CAS  Google Scholar 

  16. Teh LS, Manning J, Moore T, et al. Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 1995 Jul; 34(7): 636–41

    Article  PubMed  CAS  Google Scholar 

  17. Franks AG. Topical glyceryl trinitrate as adjunctive treatment in Raynaud’s disease. Lancet 1982 Jan 9; 1(8263): 76–7

    Article  PubMed  Google Scholar 

  18. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005 Nov 8; 112(19): 2980–5

    PubMed  CAS  Google Scholar 

  19. DiGiacomo RA, Kremer JM, Shad DM. Fish-oil dietary supplementation in patients with Raynaud’s: a double-blind, controlled, prospective study. Am J Med 1989 Feb; 68(2): 158–64

    Article  Google Scholar 

  20. Belch JJ, Shaw B, O’Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud’s phenomenon: a double blind study. J Thromb Haemost 1985 Aug 30; 54(2): 490–4

    CAS  Google Scholar 

  21. Muir AH, Robb R, McLaren M, et al. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo controlled trial. Vasc Med 2002; 7(4): 265–7

    Article  PubMed  Google Scholar 

  22. Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud’s syndrome with traditional Chinese acupuncture. J Intern Med 1997 Feb; 241(2): 119–24

    Article  PubMed  CAS  Google Scholar 

  23. Al-Awami M, Schillinger M, Maca T, et al. Low-level laser therapy treatment of primary and secondary Raynaud’s phenomenon. Vasa 2004 Feb; 33(1): 25–9

    Article  PubMed  CAS  Google Scholar 

  24. Ko GD, Berbrayer D. Effect of ceramic-impregnated ‘thermoflow’ gloves on patients with Raynaud’s syndrome: randomized, placebo-controlled study. Altern Med Rev 2002 Aug; 7(4): 328–35

    PubMed  Google Scholar 

  25. Baron M. Personal communication of unpublished data from the Canadian Scleroderma Research Group (CSRG)

  26. Wigley FM, Seibold JR, Wise RA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992 Sep; 19(9): 1407–14

    PubMed  CAS  Google Scholar 

  27. Seibold JR, Matucci-Cerinic M, Denton CP, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis. Ann Rheum Dis 2006; 65 Suppl. II: 90

    Google Scholar 

  28. Black C, Denton CP, Furst DE, et al. Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis: open label extension to a double-blind trial. Ann Rheum Dis 2006; 65 Suppl. II: 384

    Google Scholar 

  29. Varga J. New hope for systemic sclerosis patients with digital ulcers. Curr Rheumatol Rep 2005 Apr; 7(2): 127–8

    Article  PubMed  Google Scholar 

  30. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004 Dec; 50(12): 3985–93

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author would like to acknowledge that the paragraph on complementary and alternative treatments was contributed by Deanne Malenfant and that the manuscript was prepared by Gillian Ouimet. No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Janet E. Pope.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pope, J.E. The Diagnosis and Treatment of Raynaud’s Phenomenon. Drugs 67, 517–525 (2007). https://doi.org/10.2165/00003495-200767040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767040-00003

Keywords

Navigation